NALIRIFOX and other nal-IRI based regimen as sequential therapy after FOLFIRINOX in unresectable pancreatic cancer

Key Points

• This research aims to evaluate the efficacy of NALIRIFOX as sequential therapy following FOLFIRINOX in patients with unresectable pancreatic cancer.
• Investigated the regimen of nal-IRI combined with other agents after initial treatment with FOLFIRINOX.
• Utilized clinical data to compare treatment outcomes.
• Focused on patients with advanced pancreatic cancer.
• NALIRIFOX showed improved treatment response rates compared to traditional therapies.
• Patients receiving nal-IRI experienced longer progression-free survival (exact metrics not specified).
• Side effects were manageable compared to other chemotherapy regimens.